Zilovertamab vedotin: early efficacy in relapsed or refractory DLBCL in combination with R-GemOx?

Interim data from the dose-confirmation phase of the waveLINE-003 trial suggest that zilovertamab vedotin, a novel antibody-drug conjugate targeting ROR1, may offer promising efficacy when added to standard rituximab plus gemcitabine-oxaliplatin (R-GemOx) in participants with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) ineligible for CAR T-cell therapy or autologous stem-cell transplantation. The phase 2/3 MK-2140-003/waveLINE-003 study (NCT05139017) enrolled adult participants with DLBCL after at least 1 prior line of therapy in cohort A. Participants were treated with zilovertamab vedotin (an antibody–drug conjugate comprising a monoclonal antibody recognising extracellular ROR1, a cleavable linker, and the anti-microtubule cytotoxin monomethyl auristatin E) at escalating doses (1.5, 1.75, or 2.0 mg/kg) in combination with R-GemOx every 3 weeks for a minimum of 6 cycles. The prim...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 30 July 2025